{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:38:02Z","timestamp":1792874282676,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA196067"],"award-info":[{"award-number":["U24CA196067"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180822"],"award-info":[{"award-number":["U10CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijrobp.2026.09.013","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:46:46Z","timestamp":1790725606000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tocilizumab, Atezolizumab, and Stereotactic Radiation Therapy in Recurrent Glioblastoma: Primary Analysis of Safety and Efficacy of a Phase 2 Trial, NRG Oncology-BN010"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7117-0539","authenticated-orcid":false,"given":"Stephen J.","family":"Bagley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yin C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh R.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Brem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjini","family":"Tolakanahalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Zureick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio M.","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalanthica V.","family":"Yogendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazmin","family":"Odia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Ney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Lobbous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Mohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Zukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Tang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga H.","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhee","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.09.013_bib0001","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0002","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/neuonc\/noaf134","article-title":"Improvements in survival for glioblastoma in the post-Stupp protocol era","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0003","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0004","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The checkMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0006","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00618","article-title":"Dual immune check point blockade in MGMT-unmethylated newly diagnosed glioblastoma: NRG oncology BN007, a randomized phase II\/III clinical trial","volume":"43","author":"Lassman","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0007","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0008","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0009","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","article-title":"Combination therapy with Anti-PD-1, Anti-TIM-3, and focal radiation results in regression of murine gliomas","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11060-020-03459-y","article-title":"Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice","volume":"147","author":"Stessin","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0011","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0012","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/1535-7163.MCT-22-0516","article-title":"Predicting the abscopal effect: Associated tumor histologic subtypes and biomarkers","volume":"22","author":"Nelson","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0013","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-24-2522","article-title":"Facts and hopes in radioimmunotherapy of oligometastatic disease","volume":"31","author":"Huang","year":"2025","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0015","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0016","doi-asserted-by":"crossref","first-page":"eabm5214","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Science."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0017","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/2159-8290.CD-20-0219","article-title":"Phenotypic mapping of pathologic cross-talk between glioblastoma and innate immune cells by synthetic genetic tracing","volume":"11","author":"Schmitt","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0018","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0019","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0020","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1158\/0008-5472.CAN-24-0018","article-title":"Tumor-associated microglia secrete extracellular ATP to support glioblastoma progression","volume":"84","author":"Wu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0021","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178628","article-title":"Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma","volume":"134","author":"Liu","year":"2024","journal-title":"J Clin Invest."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0022","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ccell.2021.05.003","article-title":"Macrophage-tumor cell intertwine drives the transition into a mesenchymal-like cellular state of glioblastoma","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0023","first-page":"rs.3.rs","article-title":"Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade","author":"Baruch","year":"2023","journal-title":"Res Sq."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0024","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0026","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41467-018-03050-0","article-title":"Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2\u03b1","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0027","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/15548627.2016.1178446","article-title":"A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway","volume":"12","author":"Xue","year":"2016","journal-title":"Autophagy."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0028","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1158\/1078-0432.CCR-18-2402","article-title":"Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth","volume":"25","author":"Lamano","year":"2019","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0029","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1038\/s41467-021-23832-3","article-title":"Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0030","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-25-2922","article-title":"IL6 Supports Development of an Immunosuppressive Microenvironment and Resistance to Therapy in Glioblastoma","volume":"86","author":"Young","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0031","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0032","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas","volume":"28","author":"Fogh","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0033","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0034","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0035","article-title":"The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review","volume":"6","author":"Schonfeld","year":"2024","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0036","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/neuonc\/noad002","article-title":"Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival","volume":"25","author":"Ellingson","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0037","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: A randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0038","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(25)00642-4","article-title":"O-(2-[(18)F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA\/NOA-10 ARO2013-01): A multicentre, open-label, randomised trial","volume":"27","author":"Grosu","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0039","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/neuonc\/noaf247","article-title":"International stereotactic radiosurgery society (ISRS) practice guidelines for radiosurgery in recurrent high-grade glioma","volume":"28","author":"Pinzi","year":"2026","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0040","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0041","first-page":"vdac087","article-title":"The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: A systematic review","volume":"4","author":"Swildens","year":"2022","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0042","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/S1470-2045(24)00656-9","article-title":"Proceedings of the National cancer institute workshop on combining immunotherapy with radiotherapy: Challenges and opportunities for clinical translation","volume":"26","author":"Morris","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0043","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","article-title":"The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","volume":"21","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.528","article-title":"The impact of sequencing checkpoint inhibitors and radiotherapy on clinical outcomes of patients with melanoma brain metastases: Meta-analysis of comparative studies","volume":"120","author":"Haddad","year":"2024","journal-title":"Int J Radiat Oncol, Biol, Phys."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0045","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat Immunol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0046","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/neuonc\/noaa260","article-title":"Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: Results from a phase I study","volume":"23","author":"Sahebjam","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0047","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: Clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0048","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0049","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.2004","article-title":"PD1 inhibition and GITR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study","volume":"41","author":"Bagley","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijrobp.2026.09.013_bib0050","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","article-title":"Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration","volume":"8","author":"Kostopoulos","year":"2024","journal-title":"Blood Adv."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626043117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626043117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:24:12Z","timestamp":1792873452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626043117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S0360301626043117"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.09.013","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab, Atezolizumab, and Stereotactic Radiation Therapy in Recurrent Glioblastoma: Primary Analysis of Safety and Efficacy of a Phase 2 Trial, NRG Oncology-BN010","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}